Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan
Launch And NHI Listing Follows Approval In March This Year
A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.
You may also be interested in...
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.